Sanofi and Regeneron are Strengthening their Medication Profile Image Credits: The Dermatology Digest Progress Sanofi and Regeneron pharmaceutical companies are leading the way with their popular biologic Dupixent. These companies are strengthening their eczema efficacy profile. The biologic Du...
Blue Cross's Partnership Strategy to Expand the GBA Healthcare Sector Image Credits: Insurance Asia Alliance Blue Cross (Asia Pacific) Insurance's partnership with four healthcare centers and the hospital is paving the way for the expansion of the healthcare and insurance sector. The partnershi...
Baroda BNP Paribas MF Introduced a Healthcare and Wellness Fund Image Credits: Baroda BNP Paribas Announcement Baroda BNP Paribas Asset Management India has introduced a new thematic equity scheme. A scheme is known as ‘Baroda BNP Paribas health and wellness fund. This new fund offer is r...
An Advancement in Science and Technology, a Contribution to Vietnam’s Healthcare Sector Image Credits: Business Wire Event The leading pharmaceutical industries showcased public-private partnership and innovation at the Healthcare Innovation Forum 2025, which was co-hosted in Hanoi by the...
OPTIC and Mechanica Partnership to Initiate AI-driven Venture Announcement Mechanica, a venture creation firm, to advantage Optic’s Bioptic platform innovatively. The expanded strategic collaboration intends to discover next-generation biotechnology companies. The collaborative initiative ...
Alnylam’s Goal is to Expand Medication Image Credits: Biospace Announcement Alnylam received two FDA approvals for Sanofi’s Qfitlia in hemophilia A and B, and Amvuttra in transthyretin-mediated amyloidosis. The approval is a part of Alnylam, along with other companies. Companies suc...
‘Sarepta’ Transitional Shift to Gene Therapy Development Image Credits: Biospace Platform Technology The FDA announced Sarepta Therapeutics as the FDA’s first-ever publicly documented platform technology designation. A designation for a popular vector known as ‘rAAVrh74&...
Pharmaceutical Companies Enter a New Era of Acquisitions Announcement Sanofi, a leading healthcare and pharmaceutical company, received a badge as the biggest buyer with a major contribution to rare disease specialist blueprint medicines of 9.5 billion. Whereas, Bristol-Myers Squibb offered a me...
A Drug Compilation for Small-cell Lung Cancer Image Credits: Fierce Pharma Announcement The Jazz and Roche pharmaceuticals have introduced an upgraded phase 3 data of the combined medicines Zepzelca and Tecentriq. This solution is planning to win FDA approval as a drug cocktail for small-cell l...
Image Credit: Reuters Amgen’s Imdelltra drug minimizes the risk of death by 40% in comparison to chemotherapy, mainly for small-cell lung cancer patients. The drug will help cure these patients after their worst condition, after the initial round of chemotherapy. The phase 3 trial of 509 pa...
